Gilead Sciences, Inc. with ticker code (GILD) have now 26 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The range between the high target price and low target price is between $119.00 and $67.00 with the average target price sitting at $81.02. Given that the stocks previous close was at $73.50 this indicates there is a potential upside of 10.2%. The 50 day MA is $67.75 and the 200 day moving average is $73.48. The market cap for the company is 95.32B. The stock price is currently at: $76.51 USD
The potential market cap would be $105,072,448,274 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 212.53, revenue per share of $22.00 and a 10.5% return on assets.
Gilead Sciences, Inc. is a biopharmaceutical company. The Company is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company offers products in HIV, Onocolgy, Liver Disease, Vekulaery, and Other. Under HIV, it offers Biktarvy, Complera/Eviplera, Genvoya, Odefsey, Stribild, and Truvada. Its Veklury (remdesivir) is a nucleotide analog RNA polymerase inhibitor indicated for the treatment of coronavirus disease 2019 (COVID-19). Under oncology it offers cell therapy containing Tecartus and Yescarta. Under this Liver Disease consists of Chronic hepatitis C virus (HCV) (Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir) and Chronic hepatitis B virus (HBV) / hepatitis delta virus (HDV) (Vemlidy and Viread). The Company’s other products include AmBisome and Letairis. It also operates a portfolio of small molecule inhibitors targeting PARP1 for oncology and MK2 for inflammatory diseases.
